Fox Run Management’s Pacira BioSciences PCRX Stock Holding History

Fox Run Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,092	Closed	-$365K	–	1153
2025 Q4	$365K	Buy	+14,092	New	+$335K	0.06%	630
2023 Q2	–	Sell	-8,963	Closed	-$366K	–	891
2023 Q1	$366K	Sell	8,963 -7,987	-47%	-$318K	0.12%	340
2022 Q4	$654K	Buy	+16,950	New	+$825K	0.26%	90
2019 Q3	–	Sell	-9,078	Closed	-$395K	–	514
2019 Q2	$395K	Buy	9,078 +237	+3%	+$10.1K	0.26%	134
2019 Q1	$336K	Buy	+8,841	New	+$345K	0.19%	233
2016 Q4	–	Sell	-13,400	Closed	-$459K	–	629
2016 Q3	$459K	Buy	13,400 +100	+0.8%	+$3.92K	0.27%	127
2016 Q2	$449K	Buy	+13,300	New	+$654K	0.22%	153

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fox Run Management's PCRX Position: Q1 2026 in Review

Fox Run Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 14,092 shares — an estimated $365K sold.

Fox Run Management first reported a position in PCRX in Q2 2016 and held it in 7 quarters. The position peaked at $654K in Q4 2022. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Fox Run Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 14,092 Pacira BioSciences shares in Q1 2026, an estimated $365K.
Fox Run Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 7 quarters.
Fox Run Management's Pacira BioSciences position peaked at $654K in Q4 2022.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.